Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy

British Journal of Dermatology

Volumn 156, Issue 6, 2007, Pages 1321-1327

  Kreuter, A ^a   Tomi, N S ^a   Weiner, S M ^b   Huger, M ^a   Altmeyer, P ^a   Gambichler, T ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

20 MHz ultrasound scan; Colorimetry; Cutaneous Lupus Erythematosus Disease Area and Severity Index; Mycophenolate sodium; Subacute cutaneous lupus erythematosus

Indexed keywords

MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MONOTHERAPY; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; STANDARD; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447102837     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07826.x     Document Type: Article

References (33)

1. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979 115: 1409 15.
2. Sontheimer RD, Maddison PJ, Reichlin M et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982 97: 664 71.
3. Lee LS, Alvarez K, Gross T, Harley JB. The recognition of human 60-kDa Ro ribonucleoprotein particles by antibodies associated with cutaneous lupus and neonatal lupus. J Invest Dermatol 1996 107: 225 8.
4. Chlebus E, Wolska H, Blaszczyk M, Jablonska S. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. J Am Acad Dermatol 1998 38: 405 12.
5. Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 1988 31: 1007 13.
6. Furner BB. Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 1990 29: 542 7.
7. Callen JP. Update on the management of cutaneous lupus erythematosus. Br J Dermatol 2004 151: 731 6.
8. Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001 28: 1 23.
9. Salvatori M, Holzer H, de Mattos A et al. on behalf of the ERLB301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004 4: 231 6.
10. Chan L, Mulgaonkar S, Walker R et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006 81: 1290 7.
11. Albrecht J, Taylor L, Berlin JA et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005 125: 889 94.
12. Fullerton A, Fischer T, Lahti A et al. Guidelines for measurement of skin colour and erythema. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis 1996 35: 1 10.
13. Callen J. Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2002 16: 245 64.
14. Isaacson D, Elgard M, Turner M. Antimalarials in dermatology. Int J Dermatol 1982 21: 379 95.
15. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000 42: 983 7.
16. Gallego H, Crutchfield CE, Lewis EJ, Gallego HJ. Report of an association between discoid lupus erythematosus and smoking. Cutis 1999 63: 231 4.
17. Boeckler P, Milea M, Meyer A. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 2005 152: 265 70.
18. Miot HA, Bartoli Miot LD, Haddat GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005 211: 118 22.
19. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leucocytoclastic vasculitis. Arch Dermatol 1991 127: 515 22.
20. McCune WL, Riskalla MM. Mycophenolate mofetil: a magic bullet for lupus? J Rheumatol 2005 32: 967 70.
21. Heymann WR. Mycophenolate mofetil. J Am Acad Dermatol 2005 53: 1045 6.
22. Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001 137: 235 6.
23. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001 45: 142 4.
24. Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 2002 138: 1616 18.
25. Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002 147: 174 8.
26. Pisoni CN, Obermoser G, Cuadrado MJ et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005 23: 393 6.
27. Cetkovska P, Pizinger K. Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil. Int J Dermatol 2006 45: 320 2.
28. Kitchin JE, Pomeranz MK, Pak G et al. Rediscovering mycophenolic acid: a review of its mechanisms, side effects, and potential uses. J Am Acad Dermatol 1997 37: 445 9.
29. Kreuter A, Gambichler T, Breuckmann F et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004 51: 407 10.
30. Kreuter A, Hyun J, Stücker M et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006 54: 440 7.
31. Wenzel J, Uerlich M, Wörrenkämper E et al. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol 2005 153: 1011 15.
32. Wenzel J, Gerdsen R, Uerlich M et al. Lymphocytopenia in lupus erythematosus: close in vivo association to autoantibodies targeting nuclear antigens. Br J Dermatol 2004 150: 994 8.
33. Wenzel J, Brahler S, Bauer R et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005 153: 157 62.